These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
218 related items for PubMed ID: 30285275
21. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials. Devinsky O, Thiele EA, Wright S, Checketts D, Morrison G, Dunayevich E, Knappertz V. Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183 [Abstract] [Full Text] [Related]
22. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes. Jensen HS, Nichol K, Lee D, Ebert B. PLoS One; 2014 Dec; 9(2):e88456. PubMed ID: 24533090 [Abstract] [Full Text] [Related]
23. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Lattanzi S, Trinka E, Striano P, Zaccara G, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532 [Abstract] [Full Text] [Related]
24. Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, Dean L. ; 2012 Jun. PubMed ID: 31550100 [Abstract] [Full Text] [Related]
30. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A. Drug Metab Dispos; 2006 Apr; 34(4):608-11. PubMed ID: 16415114 [Abstract] [Full Text] [Related]
31. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. Brain Dev; 2004 Dec; 26(8):530-4. PubMed ID: 15533655 [Abstract] [Full Text] [Related]
32. The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction. Osborn M, Abou-Khalil B. Epilepsy Behav; 2023 May; 142():109156. PubMed ID: 37037060 [Abstract] [Full Text] [Related]
33. Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy. Yamamoto Y, Takahashi Y, Imai K, Takahashi M, Nakai M, Inoue Y, Kagawa Y. Eur J Clin Pharmacol; 2014 Oct; 70(10):1203-10. PubMed ID: 25048408 [Abstract] [Full Text] [Related]
34. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects . Boyd B, Smith S, Gammaitoni A, Galer BS, Farfel GM. Int J Clin Pharmacol Ther; 2019 Jan; 57(1):11-19. PubMed ID: 30336805 [Abstract] [Full Text] [Related]
35. [A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. Nakajima H. Nihon Yakurigaku Zasshi; 2001 Aug; 118(2):117-22. PubMed ID: 11530681 [Abstract] [Full Text] [Related]
38. Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center. Lee EH, Yum MS, Choi HW, Ko TS. Clin Neuropharmacol; 2013 Aug; 36(1):4-7. PubMed ID: 23334068 [Abstract] [Full Text] [Related]
39. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Perucca E, Cloyd J, Critchley D, Fuseau E. Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564 [Abstract] [Full Text] [Related]
40. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Nishimura S, Kasai R, Ikeda H, Takayama R, Mogami Y, Yamaguchi T, Terada K, Matsuda K, Inoue Y, Kagawa Y. Ther Drug Monit; 2013 Jun; 35(3):305-12. PubMed ID: 23666564 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]